Confirmed cases of Covid-19 have risen by 20 across Cumbria in the last 24 hours.

Public Health England's latest testing data published this evening (April 13) shows the largest rise has come in South Lakeland, where eight positive cases have been identified.

Across Allerdale, Barrow, Carlisle and Copeland, three new infections were confirmed in each borough.

Eden saw its cases fall by one, with overall positive infections revised.

This has happened many times during the pandemic and is likely due due to false-positive rapid test results.

Cumbria has now seen 28,048 confirmed cases of Covid-19 since the very beginning of the pandemic

Cumbria's daily Covid cases by borough as of Tuesday, April 13

The data below includes the total number of cases and overall infection rate for each area since the pandemic began. Many of these cases will no longer be active.

Allerdale: 5,035 (+3), 5,150.3 per 100,000

Barrow-in-Furness: 4,251 (+3), 6,340.1 per 100,000

Carlisle: 8,198 (+3), 7,543.4 per 100,000

Copeland: 3,132 (+3), 4,593.5 per 100,000

Eden: 2,974 (-1) 5,584.7 per 100,000

South Lakeland: 4,463 (+8) 4,246.9 per 100,000

The Department of Health and Social Care (DHSC) has today insisted Johnson & Johnson’s decision to delay the rollout of its vaccine in Europe would not derail the UK’s programme to offer a jab to all adults by the end of July.

The UK has 30 million doses of the Johnson & Johnson product on order, but it has yet to be authorised for use by the independent Medicines and Healthcare Products Regulatory Agency (MHRA).

A DHSC spokesman said: “Our vaccination programme continues to make phenomenal progress – with over 40 million vaccines administered so far.

“We have hit our target to offer a vaccine to everyone in phase one of the vaccination programme and we are on track to offer a jab to all adults by the end of July.”

The 30 million doses are expected to arrive in the second half of 2021 if approved by the MHRA.

The regulator’s director of licensing Dr Siu Ping Lam said: “No vaccine would be authorised for use in the UK unless the expected high standards of safety, quality and effectiveness have been met.

“Vaccine safety is of paramount importance and we will monitor and evaluate any safety reports received promptly and robustly before a decision is made, working and sharing safety data with international regulators as necessary.”

For the latest news and breaking news visit the CumbriaLive website.

You can also find CumbriaLive content on the LancsLive app for free, available on iPhone here and Android here